You can buy or sell Allergan and other stocks, options, ETFs, and crypto commission-free!
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. Read More The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.
52 Week High
52 Week Low
Allergan And Cenicriviroc In NASH: The Forgotten
Overall, this weekly newsletter provides news-related events on stocks focused on the development of liver therapeutics. For accelerated conditional approval on FDA Subpart H, cenicriviroc must achieve the primary clinical endpoint of ≥1 stage improvement in liver fibrosis without worsening of NASH at 12 months. The top-line Phase 3 interim data readout on the 52-week study of cenicriviroc in patients with biopsied NASH fibrosis should be announced by Q4 2020. Allergan’s lead investigative drug candidate...
Allergan wins less than $50,000 in case against compounder Imprimis
A federal jury on Thursday awarded Allergan PLC less than $50,000 of the millions of dollars it sought in a false advertising lawsuit seeking to stop Imprimis Pharmaceuticals Inc from selling certain compounded drugs that bypass regulatory approval, including a cheaper alternative to Allergan’s dry eye drug Restasis, according to a lawyer for Imprimis.
Yahoo FinanceMay 15
Allergan to Present VRAYLAR® (cariprazine) Data at the American Psychiatric Association 2019 Annual Meeting Highlighting Continued Commitment to Mental Health
Abstracts will showcase research on VRAYLAR, including a focus on an investigational use for the treatment of bipolar depression FDA action on supplemental New Drug Application (sNDA) for VRAYLAR for the treatment of bipolar depression is expected in first half this year DUBLIN, May 15, 2019 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company, today announced it will showcase data during the upcoming American Psychiatric Association (APA) Annual Meeting in San Francisco, May 18 – M...
$3.55 per share
$3.79 per share